Web Results


Nov 16, 2017 ... The petitioner, M.M., an infant, by her mother, is one of nineteen minor plaintiffs who alleged that they sustained birth defects from their mother's use of the prescription anti-depressant Zoloft. The respondent, Pfizer, manufactures and markets Zoloft. The remaining respondents, Roerig and Greenhouse, are ...


Oct 9, 2012 ... B. The Relators listed herein have filed the following quitam actions against Pfizer. (collectively the “Civil Actions"):. (1) United States et al. ex rel. Blair Collins v. Pfizer, Inc.,. Civ. No. 04-11780-DPW (D. Mass.); (2) United States et al. ex rel. John Kopchinski v. Pfizer, Inc. et al.,. Civ. No. 05-CV-12115 (D. Mass.); ...


Parties, docket activity and news coverage of federal case American Sales Company, LLC v. Pfizer, Inc. et al, case number 2:14-cv-00361, from Virginia Eastern Court.


Mar 1, 2016 ... Accurate diagnosis of TTR‐FAP is often delayed for years (Planté‐Bordeneuve et al., 2007; Koike et al., 2011; Dohrn et al., 2013; Adams et al., 2014 ). Making an accurate diagnosis is ... The pattern of amyloid deposition may also play a role ( Bergström et al., 2005; Ihse et al., 2013 ). JNS-12153-FIG-0001-b.


Jul 26, 2016 ... Background. painDETECT is a screening measure for neuropathic pain. The nine -item version consists of seven sensory items (burning, tingling/prickling, light touching, sudden pain attacks/electric shock-type pain, cold/heat, numbness, and slight pressure), a pain course pattern item, and a pain radiation ...


Apr 15, 2015 ... Methods. Scores on the nine-item painDETECT (seven pain symptom items, one pain course pattern item, one pain radiation item) range from −1 to 38; scores ≥ 19 indicate NeP is likely (>90% probability). The seven-item version (only pain symptoms) score range is 0 to 35. painDETECT was administered ...


2Pfizer Inc., Groton/New London, Connecticut, USA ... Citation: Gandelman K, Malhotra B, LaBadie RR, Crownover P, Bergstrom T (2011) Analytes of Interest and Choice of Dose: Two Important Considerations in the Design of Bioequivalence Studies with ..... Cánovas M, Delgadillo J, Torres F, Riba N, Cebrecos J, et al.


Apr 16, 2013 ... Correspondence: Dr A Sadosky, Health Economics and Outcomes Research, Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA. E-mail: ... Raichle et al. found that as pain severity increased among subjects with post-SCI pain, pain interference with function and disability increased. In another ...